EXAGEN INC. (XGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
XGN Stock Summary
- XGN has a market capitalization of $36,882,043 -- more than approximately just 12.21% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, EXAGEN INC is reporting a growth rate of 82.03%; that's higher than 84.25% of US stocks.
- In terms of volatility of its share price, XGN is more volatile than 93.62% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to EXAGEN INC, a group of peers worth examining would be SGHT, EKSO, AWH, CXM, and NRDS.
- XGN's SEC filings can be seen here. And to visit EXAGEN INC's official web site, go to avisetest.com.
XGN Valuation Summary
- In comparison to the median Healthcare stock, XGN's price/sales ratio is 82.98% lower, now standing at 0.8.
- Over the past 42 months, XGN's price/earnings ratio has gone up 10.4.
Below are key valuation metrics over time for XGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XGN | 2023-03-17 | 0.8 | 0.7 | -0.9 | -0.1 |
| XGN | 2023-03-16 | 0.8 | 0.7 | -1.0 | -0.1 |
| XGN | 2023-03-15 | 0.9 | 0.7 | -1.0 | -0.1 |
| XGN | 2023-03-14 | 0.9 | 0.7 | -1.0 | -0.1 |
| XGN | 2023-03-13 | 0.9 | 0.7 | -1.0 | -0.1 |
| XGN | 2023-03-10 | 0.9 | 0.7 | -1.0 | -0.1 |
XGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XGN has a Quality Grade of D, ranking ahead of 19.97% of graded US stocks.
- XGN's asset turnover comes in at 0.436 -- ranking 56th of 81 Healthcare stocks.
- 500 - Internal server error
The table below shows XGN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.436 | 0.597 | -0.539 |
| 2021-03-31 | 0.457 | 0.611 | -0.455 |
| 2020-12-31 | 0.519 | 0.606 | -0.452 |
| 2020-09-30 | 0.474 | 0.575 | -0.457 |
| 2020-06-30 | 0.453 | 0.560 | -0.424 |
XGN Price Target
For more insight on analysts targets of XGN, see our XGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
XGN Stock Price Chart Interactive Chart >
XGN Price/Volume Stats
| Current price | $2.35 | 52-week high | $9.44 |
| Prev. close | $2.26 | 52-week low | $2.04 |
| Day low | $2.04 | Volume | 88,777 |
| Day high | $2.62 | Avg. volume | 20,244 |
| 50-day MA | $2.64 | Dividend yield | N/A |
| 200-day MA | $3.86 | Market Cap | 38.21M |
EXAGEN INC. (XGN) Company Bio
Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand.
Latest XGN News From Around the Web
Below are the latest news stories about EXAGEN INC that investors may wish to consider to help them evaluate XGN as an investment opportunity.
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2022, after the market close on Monday, March 20, 2023. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT). Interested parties may access the conference call by |
Exagen Inc. to Participate in Upcoming March ConferencesSAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following March investor conferences. Cowen 43rd Annual Health Care Conference March 6-8, 2023, at the Boston Marriott Copley Place in Boston, MA John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a fireside chat on Monday, March 6th at 10:30 AM ET |
Exagen Inc. (NASDAQ:XGN) insider upped their holding earlier this yearInsiders were net buyers of Exagen Inc.'s ( NASDAQ:XGN ) stock during the past year. That is, insiders bought more... |
Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceSAN DIEGO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023 in Snowbird, UT. Management will be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG. About Exagen Inc. Exagen is a leading provider of autoimmune diagnostic, pro |
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of DirectorsSAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board. Dr. Nova currently serves as President of Veracyte's (Nasdaq: VCYT) U.S. CLIA business where |
XGN Price Returns
| 1-mo | -9.62% |
| 3-mo | -2.89% |
| 6-mo | -40.51% |
| 1-year | -73.48% |
| 3-year | -85.22% |
| 5-year | N/A |
| YTD | -2.08% |
| 2022 | -79.36% |
| 2021 | -11.89% |
| 2020 | -48.03% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...